Jubilant Life Sciences is currently trading at Rs. 134.55, up by 7.80 points or 6.15% from its previous closing of Rs. 126.75 on the BSE.
The scrip opened at Rs. 128.05 and has touched a high and low of Rs. 139.40 and Rs. 128.05 respectively. So far 36,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 248.25 on 10-Dec-2012 and a 52 week low of Rs. 65.10 on 28-Aug-2013.
Last one week high and low of the scrip stood at Rs. 139.40 and Rs. 117.45 respectively. The current market cap of the company is Rs. 2,215.00 crore.
The promoters holding in the company stood at 53.95% while Institutions and Non-Institutions held 28.41% and 17.65% respectively.
Jubilant Life Sciences, an integrated Pharmaceuticals and Life Sciences Company has received Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (US FDA) for Quetiapine Fumarate Tablet, 25 mg (base), the generic version of AstraZeneca's Seroquel, which is an atypical antipsychotic medication indicated for the treatment of schizophrenia, and for the treatment of acute manic episodes associated with bipolar disorder. The current total market size for this product as per IMS is $59 million per annum.
Jubilant Life Sciences is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. As on September 30, 2013, Jubilant Life Sciences had a total of 676 filings for formulations of which 218 have been approved in various regions of the world. This includes 58 ANDAs filed in the US and 48 Dossier filings in Europe.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |